Treosulfan-based conditioning regimens for alloSCT in patients with myeloid malignancies
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on the long-term safety and efficacy of treosulfan-based conditioning regimens for allogeneic stem cell transplantation (alloSCT). Dr Gavriilaki highlights the favorable outcomes of the FT14 regimen, which combines fludarabine with treosulfan, in patients with myeloid malignancies, expanding the patient population eligible for alloSCT. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
